Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2026 Q1 | Apr 10, 2026 | Cedar Grove Capital Management | -23.0% | -23.0% | ABVX, EVLV, HIMS, KITS.TO, LNSR, MTY.TO, NKTR, OSW, REAL, SNWV, TOI, WW | Biotechnology, consumer, healthcare, Long/Short, Multi-Strategy, small cap, special situations | MTY.TO NKTR ABVX TOI SNWV EVLV REAL KITS.TO |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Fund Letters | Cedar Grove Capital Management | Nektar Therapeutics | Biotechnology | Biotechnology | Bull | NASDAQ | acquisition target, Atopic Dermatitis, biotechnology, JAK Inhibitors, Phase 3, Quarterly Dosing, safety profile, Special situations | View Pitch |
| Jan 23, 2026 | Twitter / X | @A_May_MD | Nektar Therapeutics | Health Care | Biotechnology | Bull | NASDAQ | cybersecurity, Easi, Easi Reduction, Mean Easi, Nktr, Pbo Adj, Photonics, Week | View Pitch |
| Jan 22, 2026 | Twitter / X | @seedy19tron | Nektar Therapeutics | Health Care | Biotechnology | Bull | NASDAQ | ATD, consumer lending, Efficacy, Immuno-oncology, Nktr, Payments, Rezpeg, Satellite | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||